Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
NGS methods enable cancer researchers to perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, and more. NGS also offers the sensitivity to detect rare somatic variants, tumor subclones, and circulating DNA fragments.
Immuno-oncology is an emerging field that has taken great strides in the fight against cancer, bolstered by a refined understanding of how tumors evade the natural immune response. Research into the mechanisms tumors use to inhibit the immune response have led to promising therapeutic targets.
Changes in gene activation or gene silencing can impact the rate of cancer progression. Studying the epigenetic changes that influence gene expression can provide insight into important tumorigenic pathways.
Genomic instability and chromosomal abnormalities are common features of cancer. Understanding these structural aberrations can inform studies of cancer etiology.
Illumina offers various NGS and microarray products and services to support cancer genomics research.
Learn more about Illumina technology and how it is being used in cancer research. Access publications, videos, webinars, and other educational resources.
TruSight Tumor 170 accurately identifies diffuse glioma genetic markers, supporting use in tumor characterization for clinical research studies.
Read Interview
Researchers are using RNA-Seq to reveal how lncRNAs could be used to identify, measure, and treat cancer.
Read Interview
Researchers use targeted RNA sequencing to understand the role of fusion genes in pediatric leukemia.
Read Interview
Learn the numerous ways that genomic technologies can be applied to tumor biology.
An overview of recent cancer genomics research publications featuring Illumina technology.
Munich Leukemia Laboratory is using NGS to gain a better understanding of leukemia and lymphoma subtypes and discover new therapeutic pathways.
A Garvan Institute sarcoma study identifies rare cancer-associated variants in the germline.
All the information you need, from BeadChips to library preparation to sequencer selection and analysis. Select the best tools for your lab.
A researcher from Massachusetts General Hospital compares sequencing results from FFPE and fresh-frozen tumor samples.
*Data on file based on a 2013 study.